This could also be explained by the GSEA results in our study that cancers that PRDM1 harbor unfavorable prognosis identified enriched GO terms of negative regulation of cell activation and regulation of lymphocyte activation that not found in cancers with favorable prognosis. The gene discussed is PRDM1; the disease is cancer.